Clinical Trial Update: Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the addition of lomustine to standard of care for patients with MGMT methylated, IDH-wildtype glioblastoma and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• Lomustine (Lomustine)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 3 | Status: RECRUITING